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2006 – 2008 Veterans Health Administration administrative data. There were 2,462
colorectal cancer patients receiving chemotherapy to estimate the effect of ESA on
mortality. Propensity score weighted Cox proportional hazard regressions were
performed. An interaction between ESAs and granulocyte colony stimulating fac-
tors (G-CSFs) was assessed. RESULTS: Overall, 12.7% of patients receiving chemo-
therapy in the cohort used ESAs at some time during the follow-up period. The
mean age of patients was 65.3 (standard deviation: 10.50) ranged from 22 to 97
years. The unadjusted Kaplan-Meier curves showed worse survival for ESA users
than non-users. There was no difference in survival between epoetin and darbe-
poetin. The estimated hazard ratio (HR) of ESA use for mortality was 2.045 (95% CI
 1.799 – 2.326) in a propensity score weighted model. The parameter estimate of
the interaction term between ESAs and G-CSFs was statistically significant
(-0.51574with standard error 0.20183, p0.0106). In the stratified analysis, the HR
was attenuated among the group of G-CSF users; HR  1.392; 95%CI  0.961, 2.017
for G-CSF users versusHR 2.327; 95%CI 2.027, 2.672 for non-users. This confirms
that there is an interaction between ESAs and G-CSFs. CONCLUSIONS: The use of
ESA was associated with decreased survival in colorectal cancer patients receiving
chemotherapy. There was no difference in the risks between ESA agents. The di-
rection of estimates was consistent with the results from the meta-analyses of
randomized clinical trials. Our study exclusively focused on colorectal cancer pa-
tients who were actively receiving chemotherapy and compared mortality rates
between ESA users and non-users in the study population. Our findings signifi-
cantly add to knowledge in oncology care in community practice.
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OBJECTIVES: Lenalidomide (LEN) and bortezomib (BORT) are effective drugs for the
treatment of refractory MM. Both agents have demonstrated an improvement in
disease response, progression free (PFS) and overall survival (OS) in the refractory
MM setting. NNT represents the number of patients that need to be treated with a
new intervention in order to have one additional patient deriving benefit, and is a
powerful approach that can be used to make sense of numerical results from clin-
ical trials. The NNT approach was used in the current study to compare LEN and
BOR in patients with relapsed MM. METHODS: The pivotal randomized trials for
LEN (Weber, Dimopoulos, 2007) and BORT (Richardson, 2005) were reviewed. A key
requirement for a NNT comparative analysis is that all outcomes be measured
against a comparable control. The NNT was then calculated for both agents with
respect to disease response and PFS at 12 months by taking the reciprocal of the
absolute differences in treatment effect between the experimental therapies and
the control group. RESULTS: For a disease response, theNNT for LEN and BORTwas
3 and 5 patients respectively; to have one additional patient achieving a disease
response. A difference in the NNT was also noted for PFS at 12 months; only 3
patients would need to be treated with LEN for an additional patient remaining
progression free compared to 9 with BORT. This is a relevant finding because it
suggests a 3 fold relative increase in clinical benefit in patients treat with LEN
compared to BORT. CONCLUSIONS: More patients treated with LEN are likely to
respond and to achieve a 12 month PFS than comparable patients treated with
BORT. Possible reasons for this effect include differences in the trial population,
extent of disease, and/or true differences in efficacy.
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OBJECTIVES: Breast cancer outcomes have improvedwith recent advancements in
diagnosis and treatment. Interest in breast cancer prevention is growing, andmore
clinical evidence is needed regarding the effects of preventive therapy, alone or in
combination, on breast cancer. METHODS: This was a nationwide case-control
analysis from the Taiwan National health Insurance Research Database. We ana-
lysed 16,847 female breast cancer cases among women older than 50 years who
were diagnosed between January 1, 2002, and December 31, 2008. A matched con-
trol group consisted of 50,460 matched subjects. Longitudinal exposure to angio-
tensin-converting enzyme (ACE) inhibitors, non-steroidal anti-inflammatory drugs
(NSAIDs), and aspirin was compared between women who had a first-time diag-
nosis of breast cancer and matched controls without a diagnosis of breast cancer.
RESULTS: The risk of breast cancer among patients taking both aspirin and ACEI
decreased as the ACEI dose increased. Among patients receiving between 28-364
cumulative defined daily doses (cDDD) of aspirin, the adjusted ORs were 0.97 (0.90-
1.06), 0.91 (0.82-1.03) and 0.79 (0.68-0.92) for women taking ACEI for 0-27, 28-364,
and 365 cDDD, respectively. Among women receiving 365 cDDD of aspirin, the
adjusted ORs were 0.91 (0.80-1.03), 0.81 (0.70-0.94) and 0.81 (0.71-0.92) as the ACEI
dose increased, respectively. Women taking non-aspirin NSAIDs along with ACEI
had the same finding. Amongwomen taking 28 - 364 cDDD of NSAIDs, the adjusted
ORs were 0.85 (0.81-0.89), 0.87 (0.81-0.94) and 0.80 (0.73-0.88) ; for women receiving
365 cDDD of NSAIDs, the adjusted ORs were 0.68 (0.62-0.74), 0.61 (0.53-0.70) and
0.60 (0.52-0.70) as the ACEI dose increased, respectively. CONCLUSIONS: The find-
ings of this nationwide case-control analysis support the hypothesis that ACE in-
hibitors enhance the antitumor effect of cyclooxygenase (COX) inhibitors on breast
cancer. There was no statistically significant association between use of any ACE
inhibitor alone and breast cancer rates.
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OBJECTIVES: Some observational studies indicate that androgen deprivation ther-
apy (ADT) for prostate cancer (PC) is associated with cardiovascular disease. How-
ever, the results are not currently identified in the Asian populations. We assessed
whether ADT is associated with cardiovascular disease, using a population-based
dataset. METHODS: This cohort study used data sourced from the Longitudinal
Health Insurance Database. A total of 693 subjects who were newly diagnosed PC
between January 1, 1998 and December 31, 2007, and followed until December 31,
2009. There were 313 subjects received ADT (GnRH agonists, oral antiandrogen, the
combination of the two, orchiectomy). Cox proportional hazardsmodels were used
to assess whether ADT was associated with coronary heart disease (CHD), stroke,
or heart failure, after adjusting for age, location, socioeconomic status, co-morbid-
ities, drug, year of diagnosis and type of procedure. RESULTS: In survival analysis,
ADT use was not associated with an increased risk of CHD (adjusted hazard ratio
[aHR]  1.08, 95% CI  0.747 to 1.557), stroke (aHR  0.97, 95% CI  0.661 to 1.414),
heart failure (aHR  1.22, 95% CI  0.791 to 1.875). GnRH agonist and combination
oral antiandrogen were both not associated with any outcomes. Low cumulative
dose (0-53 DDD) of antiandrogen was associated with significantly increased risks
of CHD (aHR  3.91, 95% CI  1.257 to 12.141). Among patients not treated with
radical prostatectomy, GnRH agonist use was associated with increased risk of
heart failure (aHR  2.32, 95% CI  1.010 to 5.324). Among patients with CHD,
combined therapy was associated with increased risk of heart failure (aHR  2.71,
95% CI 1.078 to 6.807). CONCLUSIONS: Low cumulative dose of antiandrogenwas
associated with increased risks of CHD. The use of combined therapy appears to be
associated with increased risk of heart failure in patients with CHD.
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OBJECTIVES: Venous thromboembolism (VTE) is a common complication among
cancer patients which results in significant morbidity and mortality. Although the
need to optimize the prevention of VTE has been recognized inWestern countries,
the understanding of the epidemiology of VTE in Asian countries remains limited.
The goal of this population-based observational study is to explore the epidemiol-
ogy and clinical profiles of VTE among cancer patients in Taiwan.METHODS:Using
Taiwan’s National Health Insurance Research Database, we identified newly diag-
nosed cancer patients between 2001 and 2010. Study outcome was defined as a
hospitalization with VTE diagnosis during or after the cancer diagnosis date. To
verify the accuracy of VTE diagnosis, patients must have received subcutaneous or
intravenous anticoagulants, surgical thromboectomy, angioplasty or insertion of
inferior vena cava filter during the VTE hospitalization. The incidence rate of VTE
for the entire study cohort and subgroups of patients categorized by sites of cancer
was estimated. RESULTS: Among 46,061 cancer patients, 555 (2.7 per 1000 patient-
year) patients had VTE admission (438 (78.92%) venous thrombosis, 91 (16.40%)
pulmonary embolism (PE) and 26 (4.68%) with concomitant PE and venous throm-
bosis) during or after the cancer diagnosis date. Sites of cancer with the highest
rates of VTE were myeloma, pancreas, liver, lung, and ovary, with incidence rates
were 5.52, 5.49, 4.67, 4.53, and 4.42 per 1000 patient-year, respectively. Approxi-
mately one-fifth (19.46%, n108) of VTE admission was occurred at the cancer
diagnosis date. Cumulative occurrence of VTE within 1, 3, 6, and 12 months were
26.49%, 40.18%, 49.01%, and 59.28%, respectively. CONCLUSIONS: Although the
incidence of cancer-related VTE among Taiwanese is lower than Caucasians pop-
ulation, it is not rare in specific cancer such asmyeloma, pancreas and liver cancer.
Most VTE occurred within 1 year after cancer diagnosis. Prevention of VTE may be
optimized in higher-risk patients.
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OBJECTIVES: Statin use has been increasing, especially middle-aged and elderly
patients with chronic disease, who use them continuously in Taiwan. Studies con-
ducted in the United States did not report an association between the use of statins
and breast cancer; to the best of our knowledge, no studies of a potential associa-
tion have been conducted in a Chinese population. We analyzed data from the
National Health Insurance Research Database in Taiwan to evaluate the associa-
tion between statin use and breast cancer risk. METHODS: This is a population-
based nested case-control study used data from the Taiwan National Health Insur-
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ance Research Database between 1 January 2000 and 31 December 2008. All
patients received at least two prescriptions for statins and used continuously for at
least 6months during the study periodwere included as the study cohort. Of these,
cases were identified as subjects with the first diagnosis of breast cancer and
matched to randomly selected controls. Hazard ratios were used to estimate the
risk associated with exposure to statin use and breast cancer by Cox proportional
hazards model adjusted for co-morbidities, menopause, diabetes, use of other lip-
id-lowering agents, hormone replacement therapy, cardiovascular drugs and non-
steroidal anti-inflammatory drugs. RESULTS: We identified 99 breast patients
among 17166 statin users from 2001 to 2008. The mean follow-up period was 3.5
years. We found a significant risk of breast cancer among statin users in age-
adjusted (hazard ratio(HR)1.63, 95% confidence interval: (1.301,2.033) , p 0.0001)
and multivariate analysis(HR:1.42, 95% CI: (1.103,1.825),p0.0065). The risk of
breast cancer did not differ significantly in stratified analysis of covariates. How-
ever, a suggestive increased risk of breast cancer among statin users of pre-meno-
pausal, co-administered with cardiovascular drugs and NSAIDs was found.
CONCLUSIONS: This study is likely to support an association between statin use
and breast cancer risk in the population of Chinese.
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DECREASED RISK OF PROSTATE CANCER IN TYPE 2 DIABETES PATIENTS: A
META-ANALYSIS OF COHORT STUDIES
Dipika B1, Gudala K1, Undela K1, Pramil T1, Bhansali A2
1National Institute of Pharmaceutical Education and Research, Mohali, Punjab, India,
2Postgraduate Institute of Medical Education and Research, Mohali, Mohali, India
OBJECTIVES: Emerging evidence suggests that diabetes may increase the risk of
cancers. Available evidence on prostate cancer, however, is conflicting. We there-
fore examined the association between type 2 diabetes and risk of prostate cancer
by conducting a detailed meta-analysis of prospective cohort studies published
regarding this subject. METHODS: PubMed database, CINAHL, EMBASE, and bibli-
ographies of retrieved articles were searched for prospective cohort studies (pub-
lished between 1970 and 2011) investigating the relationship between type 2 dia-
betes and prostate cancer. Pooled risk ratio (RR) was calculated using random-
effects model (DerSimonian and Laird method). Heterogeniety was calculated
using Cochrane’s Q test. To find out heterogeniety we performed subgroup analy-
sis. Sensitivity analysis and cumulative meta-analysis were also done. RESULTS:
Twenty-nine cohort studies involving 5.1 million participants and 92,331 prostate
cancer cases detected a significant inverse association between type 2 diabetes and
risk of prostate cancer (RR 0.87 (95% CI 0.80-0.94)). Sensitivity analysis done by
excluding one outlier further strengthened our negative association (RR 0.82, 95%
CI 0.76-0.84). This association was not substantially modified by Prostate-specific
antigen testing, number of covariates adjustment and adjustment for BMI or obe-
sity. Cumulative meta-analysis showed a change in trend of reporting risk of pros-
tate cancer from positive to negative in type 2 diabetes patients between 1970 and
2011. No evidence of publication bias was observed. CONCLUSIONS: Our meta-
analysis provides strongest evidence supporting that type 2 diabetes is signifi-
cantly inversely associated with risk of developing prostate cancer.
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OBJECTIVES: Studies examining the association between type 2 diabetes and the
risk of breast cancer in women have small sample sizes and inconclusive results.
This study systematically reviews the risk of breast cancer in diabetic women and
compares the risk of breast cancer in Caucasian and Asian women with type 2
diabetes. METHODS: Data for this meta-analysis were extracted from MEDLINE
and EMBASE databases from years 1975 to 2010. Initial search of risk of breast
cancer in women with type 2 diabetes yielded 33 studies. Out of the 33 studies
found in the search, 22 studies met the inclusion criteria with 16 and 6 studies
involving Caucasian and Asian women with a risk of breast cancer, respectively.
RESULTS: The 22 studies analyzed using STATA®SE version10 involved a total of
77,204women (47,083 Caucasians and 30,121Asians).Meta analysis results showed
that overall, women with type 2 diabetes had a 30.5% significantly higher risk of
breast cancer (RR, 1.305; 95% CI, 1.30-1.31). Compared to Western women, Asian
women with type 2 diabetes had 51.9% significantly higher risk of developing
breast cancer (RR, 1.519; 95% CI, 1.508-1.530). CONCLUSIONS: The study shows that
womenwith type 2 diabeteswere likely to be, as a group, at increased risk for breast
cancer, with a relatively higher risk among Asian women. The efficacy of enhance-
ments in glycemic control management, improving insulin sensitivity with exer-
cise and diet control and screening for breast cancer particularly in Asian women
with type 2 diabetes warrants further study.
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OBJECTIVES: A universally accepted staging system for hepatocellular carcinoma
(HCC) has not been adopted. The goal of this work is to assess survival and treat-
ment patterns of HCC patients stratified by the National Comprehensive Cancer
Network (NCCN) staging-guided treatment categories. METHODS: An HCC retro-
spective research registry was developed from linking records in the University of
Utah Enterprise Data Warehouse, the Utah Population Database, and the Hunts-
manCancer Institute Tumor Registry. Patient recordswere included if age 18, at
least one HCC ICD-9 code, documented hepatocellular carcinoma or cholangiocar-
cinoma in the tumor registry, and the presence of informative staging data around
the time of diagnosis. Patients were stratified by the NCCN groupings by chart
review around the time of diagnosis as either: potentially resectable or operable
(RESECT), transplantable (TRANSP), unresectable (UNRESCT), inoperable due to
performance status (INOPER), or having metastatic (METAST) disease. Treatment
patterns and survival were evaluated. RESULTS: A total of 221 patients (161 males,
72.9%) with HCC were identified. At the time of diagnosis 12.7% subjects (n28)
were considered RESCT; 14.9% (n33) TRANSP; 34.8% (n77) UNRESCT; 18.1%
(n40) INOPER, and 17% (n38) METAST. Staging informationwas not available for
5 subjects (2.3%). Kaplan-Meier analysis demonstrated statistically significant dif-
ferences in all groups except between RESCT and TRANSP patients and between
UNRESCT and INOPER patients. Themedian days of survival were 594, 562, 247, 167
and 44 for RESCT, TRANSP, UNRESCT, INOPER, and METAST patients respectively.
RESECT patients most frequently received early resection (61%) and TRANSP pa-
tients had the highest utilization of liver transplant (33%). Utilization of any treat-
ment was low in the METAST (31.6%) and INOPER (60%) groups. CONCLUSIONS:
Treatment patterns were distinct across the NCCN groupings and aligned with
NCCN treatment guidelines. Overall the NCCN groupings predict overall survival.
CANCER - Cost Studies
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OBJECTIVES: Acute Myeloid Leukaemia (AML) can be diagnosed at any age and
accounts for around a third of all leukaemia diagnoses. Treatment, which can be
given with supportive and/or curative intent, is expensive with costly medical
interventions and lengthy hospitalization (often due to complications). Despite
this, little is knownabout its lifetime economic burdenwith few studies attempting
to cost the entire treatment pathway. This investigation aimed to address these
issues by estimating the phase-specific and lifetime pathway costs of a UK cohort
of AML patients. METHODS: The Haematological Malignancy Research Network
(HMRN, www.hmrrn.org), is a population-based study, that has registered newly
diagnosed patients with haematological malignancies in two UK cancer networks.
All adults (18) newly diagnosed with AML from September 2004 to August 2007
were included in the current study (n382). The bottom-up method was used to
cost each treatment, and lifetime costs were calculated by linking the treatment
costs to the treatment pathway. Treatment pathways and medical resource con-
sumption were derived from HMRN and National Hospital Episode Statistics (HES).
Unit costs were determined from various sources, including the British National
Formulary and NHS reference costs. RESULTS: The average lifetime treatment cost
and survival life-years per patient were £40,324(554-247,432) and 5.3 (0.7-68.3)
months, respectively. This cost was largely determined by first-line treatment and
the number of relapses. The major cost-driver throughout all treatment phases
was hospitalization, followed by the costs of drugs and treatment of complication.
CONCLUSIONS:The study demonstrates that costing the treatment pathway using
the bottom-up approach is plausible. In line with existing literature, lifetime costs
of treating AML were found to be high; and it is expected that these findings could
assist decison makers to make informed treatment choices. The costing method
developed in this study could be successfully applied to other diseases with com-
plex treatment pathways.
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OBJECTIVES: For several years, cytotoxic agents have been the backbone of cancer
treatment. There has increasingly, however, been an emergence of new drugs that
are more specific to the target molecule. Some of these novel agents have resulted
in a prolongation of survival and even clinical cures in some cancers. In order to
assess the costs and overall benefits of these new drug therapies, a descriptive
evaluation across seven major tumor types was undertaken. METHODS: A litera-
ture search was conducted from 2000 to 2011 to identify randomized trials of novel
therapies in breast, lung, colorectal, kidney, lymphoma, multiple myeloma and
chronic myelogenous leukemia. Clinical outcomes in terms of progression free
(PFS) and overall survival (OS) benefit were extracted. Economic data in terms of
cost permonth of therapywas obtained from aU.S. cancer clinic. RESULTS:Almost
22 novel therapies were approved across the seven cancers. Four of the 22 (18%)
were used with a curative intent while the remainder were used in the palliative
setting (n18). Ten of these 18 latter agents (56%) also demonstrated an OS benefit.
The median month cost for novel therapies used with a curative intent and those
with a survival benefit in the palliative setting were $5450 and $6450 respectively.
In contrast, the median monthly cost for drugs that did not offer either of these
benefits was $7900. Of the agents identified, imatinib, lenalidomide, rituximab and
trastuzumab provided the greatest magnitude of benefit for both PFS and OS and
would be considered major clinical advances. CONCLUSIONS: Approximately 64%
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